From £7.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £7.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

IXICO – full-year results, how much is recent fundraising to ‘accelerate technology platform growth and global commercial reach’?

By Steve Moore | Wednesday 4 December 2024


Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


Describing itself as “a global leader in neuroscience imaging, using its AI-driven platform to help advance therapy research in neurological disorders”, IXICO (IXI) has announced results for its year ended 30th September 2024 and emphasises “the appointment of Bram Goorden as CEO towards the end of H2, the completion of an oversubscribed £4 million capital raise in October, and the launch of the group's next generation TrialTracker AI-driven imaging platform, underpinned by growth in the group's orderbook towards the end of the year”. So what of a current share price response more than 10% lower to 11p?
Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.


Filed under:



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

 

VCP

Victoria - The roll up unravels

 

HEMO

Hemogenyx is a short – target 0p

 

ECR

ECR, the timing is unfortunate

 

APH

Alliance Pharma – a recovery Buy?

 

PICH

Pitch Pit – this stinks

 

GEX

Georgina Energy: Lyin’ Yet again

Time left: 21:57:26